| http://www.w3.org/ns/prov#value | - For trials in relapsing forms of MS, comparing a new drug to inactive placebo allows a study to proceed with a relatively small number of subjects, which can ease recruitment and reduce costs, yet leaves those on placebo possibly vulnerable to the immune attacks and relapses that currently available therapies can partially prevent.
|
